Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Carone

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
The Journal of Infectious Diseases|March 26, 2026
Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV VaccinationAlisa Kachikis, Collrane Frivold, Mindy Pike, et al.
BMJ Open|June 4, 2024
Evaluation of a novel university-based testing platform to increase access to SARS-CoV-2 testing during the COVID-19 pandemic in a cohort studyJulia Catherine Bennett, Jessica O'Hanlon, Zachary Acker, et al.
Plos Computational Biology|April 2, 2019
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence featuresCraig A Magaret, David C Benkeser, Brian D Williamson, et al.
The Journal of Infectious Diseases|March 26, 2024
Comparative Diagnostic Utility of SARS-CoV-2 Rapid Antigen and Molecular Testing in a Community SettingAshley E Kim, Julia C Bennett, Kyle Luiten, et al.
Emerging Infectious Diseases|October 24, 2024
Clinical and Genomic Epidemiology of Coxsackievirus A21 and Enterovirus D68 in Homeless Shelters, King County, Washington, USA, 2019-2021Sarah N Cox, Amanda M Casto, Nicholas M Franko, et al.
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Vaccine|February 2, 2024
Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infectionJulia C Bennett, Kyle G Luiten, Jessica O'Hanlon, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
The Journal of Infectious Diseases|March 26, 2026
Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV VaccinationAlisa Kachikis, Collrane Frivold, Mindy Pike, et al.
BMJ Open|June 4, 2024
Evaluation of a novel university-based testing platform to increase access to SARS-CoV-2 testing during the COVID-19 pandemic in a cohort studyJulia Catherine Bennett, Jessica O'Hanlon, Zachary Acker, et al.
Plos Computational Biology|April 2, 2019
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence featuresCraig A Magaret, David C Benkeser, Brian D Williamson, et al.
The Journal of Infectious Diseases|March 26, 2024
Comparative Diagnostic Utility of SARS-CoV-2 Rapid Antigen and Molecular Testing in a Community SettingAshley E Kim, Julia C Bennett, Kyle Luiten, et al.
Emerging Infectious Diseases|October 24, 2024
Clinical and Genomic Epidemiology of Coxsackievirus A21 and Enterovirus D68 in Homeless Shelters, King County, Washington, USA, 2019-2021Sarah N Cox, Amanda M Casto, Nicholas M Franko, et al.
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Vaccine|February 2, 2024
Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infectionJulia C Bennett, Kyle G Luiten, Jessica O'Hanlon, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Pageof 11